Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis-Reference-Cited by-同舟云学术

Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis

Published:2015-09-11 Issue:11 Volume:138 Page:3275-3286
ISSN:0006-8950
Container-title:Brain
language:en
Short-container-title:Brain

Author:

Iaffaldano Pietro,Lucisano Giuseppe,Pozzilli Carlo,Brescia Morra Vincenzo,Ghezzi Angelo,Millefiorini Enrico,Patti Francesco,Lugaresi Alessandra,Zimatore Giovanni Bosco,Marrosu Maria Giovanna,Amato Maria Pia,Bertolotto Antonio,Bergamaschi Roberto,Granella Franco,Coniglio Gabriella,Tedeschi Gioacchino,Sola Patrizia,Lus Giacomo,Ferrò Maria Teresa,Iuliano Gerardo,Corea Francesco,Protti Alessandra,Cavalla Paola,Guareschi Angelica,Rodegher Mariaemma,Paolicelli Damiano,Tortorella Carla,Lepore Vito,Prosperini Luca,Saccà Francesco,Baroncini Damiano,Comi Giancarlo

Publisher

Oxford University Press (OUP)

Subject

Neurology (clinical)

Link

http://academic.oup.com/brain/article-pdf/138/11/3275/13798735/awv260.pdf

Reference27 articles.

1. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study

2. Observations during an elective interruption of natalizumab treatment: a post-marketing study

3. Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study

4. Severe relapses under fingolimod treatment prescribed after natalizumab

5. Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis;Journal of Neurology, Neurosurgery & Psychiatry;2024-03-27

2. Multiple faces of multiple sclerosis in the era of highly efficient treatment modalities: Lymphopenia and switching treatment options challenges daily practice;International Immunopharmacology;2023-12

3. Real-world treatment outcomes and safety of natalizumab in Finnish multiple sclerosis patients;Multiple Sclerosis Journal - Experimental, Translational and Clinical;2023-10

4. Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation;JAMA Neurology;2023-07-01

5. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis;JAMA Neurology;2023-07-01